期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

口服胺碘酮联合应用血管紧张素Ⅱ受体拮抗剂在心房颤动复律后维持窦性心律临床观察 被引量：3

Observation of amiodarone combining ARB on maintain sinus rhythm after atrial fibrillation cardioversion
下载PDF
导出
摘要 目的观察口服胺碘酮联合应用血管紧张素Ⅱ受体拮抗剂(ARB)在心房颤动复律后维持窦性心律的疗效。方法入选61例持续性心房颤动患者,随机分为两组,对照组(单纯口服胺碘酮)30例,实验组(口服胺碘酮+ARB)31例,疗程观察24个月。结果两组比较实验组窦性心律维持率明显高于对照组,有显著性差异。结论口服胺碘酮联合应用ARB可逆转左心房扩大,更有效地维持窦性心律。
作者 赵婕 张宇新 李辉 陆鹏
机构地区 黑龙江省双鸭山煤炭总医院心内科
出处 《中国心血管杂志》 2007年第1期62-63,80,共3页 Chinese Journal of Cardiovascular Medicine
关键词 心房颤动 心房重构 胺碘酮 血管紧张素Ⅱ受体拮抗剂
分类号 R541.7 [医药卫生—心血管疾病]
  • 相关文献

参考文献5

  • 1陈剑飞,黄岚.肾素-血管紧张素-醛固酮系统抑制与心房颤动[J].心血管病学进展,2006,27(1):22-23. 被引量：22
  • 2Mclrid AH, Escobar C, Rellb JM, et al, Angiotensin receptor blockar as adjunctive therapy for rhytm control in atrial fibrillation; results of the irbesartan amiodrone trial[J],Gard Electrophysiol Rev, 2003,7 : 243-245.
  • 3Kaprilian RR,Dupont E, Hafiti S, et al, Angiotensin Ⅱ recetor type Ⅰ Mora is upregulated in atria of patients with end-stage healt failure [J]. I mol cell Cardiol,1997,29:2299-2304.
  • 4Everson-Rose SA, Meyer PM, Powell LH, et al, Depression symptoms, insulir resistaree, and risk of diabetes in woman at midlife[J ]. Diabetes Care, 2005,28 : 1265-1266.
  • 5Madrial AH,Bueno MG, Rebollo J, et al. Use of inbsartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation[J ]. Circulation, 2002 ; 106 : 33-35.

二级参考文献16

  • 1Wachtell K,Lehto M, Hornestam B, et al. Losartan reduces the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy:the LIFE studv[J]. Eur Heart J, 2003, 24:504.
  • 2Finkielstein D,Schweitzer P. Role of angiotensin-oonverting enzyme inhibitors in the prevention of atrial fibrillation[J]. Am J Cardiol,2004,93:734-736.
  • 3Swedberg K, Pfeffer M, Coen-Solal A, et al. Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan:resuhs from the CHARM study[J]. J Am Coll Cardiol,2004,43 ( suppl A ) : 222 A.
  • 4Swedberg K, Pfeffer M, Coen-Solal A, et al. Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan:resuhs from the CHARM study[abstract][J]. J Am Coll Cardiol,2004,43 ( suppl A ) :222 A.
  • 5Teo K,Yusuf S,Anderson C,et al.Rationale ,design,and baseline characteristics of 2 large,simple randomized trials evaluating telmisartan,ramipril and their combination in high-risk patients:The ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment in ACE intolerant subjects with cardiovascular disease[J].Am Heart J,2004,148:52-61.
  • 6Zaman AG, Kearney MT, Schecter C, et al. Angiotensin-converting enzyme inhibitors as adjuvent therapy in patients with persistent atrial fibrillation [J]. Am Heart J ,2004,147 : 823-827.
  • 7Kumagai K, Nakashima H, Urata H ,et al. Effects of angiotensin Ⅱ type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation [J]. J Am Coll Cardiol,2003,41:2197-2204.
  • 8Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signalregulated kinase and angiotensin-converting enzyme in human atrial during atrial fibrillation[J]. J Am Coll Cardiol,2000,35 : 1669-1677.
  • 9Goette A,Arndt M ,Rocken C, et al. Regulation of angiotensin Ⅱ receptor subtypes during atrial fibrillation in humans[J]. Circulation, 2000,101 : 2678-2681.
  • 10Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure[J]. Circulation, 2001,104 :2608-2614.

共引文献21

同被引文献54

引证文献3

二级引证文献8

中国心血管杂志
2007年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部